(Q37489497)

20 August 2017

1 reference

title

Emerging therapies for chronic kidney disease: what is their role? (English)

1 reference

chronic renal insufficiency

20 August 2017

1 reference

Eswari Vilayur

1

1 reference

20 August 2017

David C H Harris

series ordinal

2

1 reference

20 August 2017

language of work or name

English

0 references

publication date

19 May 2009

1 reference

Nature Reviews Nephrology

20 August 2017

1 reference

20 August 2017

5

1 reference

20 August 2017

7

1 reference

20 August 2017

375-383

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2009.76

20 August 2017

0 references

cites work

Reduction of proteinuria by rosiglitazone in non-diabetic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Meta-analysis: the effect of statins on albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Tranilast slows the progression of advanced diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Effect of tranilast in early-stage diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Glycosaminoglycans Delay the Progression of Nephropathy in NIDDM

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Role of advanced glycation end products in diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Advanced glycation end products and diabetic nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Renoprotective effects of a novel inhibitor of advanced glycation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Hypertension and cardiovascular risk in chronic kidney disease patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Novel approaches targeted toward oxidative stress for the treatment of chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

The effect of ruboxistaurin on nephropathy in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Reversal of proteinuric renal disease and the emerging role of endothelin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Late-Onset Endothelin-A Receptor Blockade Reduces Podocyte Injury in Homozygous Ren-2 Rats Despite Severe Hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Avosentan reduces albumin excretion in diabetics with macroalbuminuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Statins for improving renal outcomes: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Correction of anemia with epoetin alfa in chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Effect of recombinant human erythropoietin on endothelial cell apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Critical missing data on erythropoiesis-stimulating agents in CKD: first beat placebo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Antiproteinuric effect of oral paricalcitol in chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Association of oral calcitriol with improved survival in nondialyzed CKD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Sirolimus reduces polycystic liver volume in ADPKD patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Pathways of caspase-mediated apoptosis in autosomal-dominant polycystic kidney disease (ADPKD).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Role of vasopressin antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Autosomal dominant polycystic kidney disease: time for a change?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Renal Bone Morphogenetic Protein-7 Protects against Diabetic Nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

FR167653 inhibits fibronectin expression and apoptosis in diabetic glomeruli and in high-glucose-stimulated mesangial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2009.76

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19455178

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Selective ET(A) receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19455178

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRNEPH.2009.76

1 reference

Dimensions Publication ID

20 August 2017

0 references

1 reference